Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast

Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast

Bibliographic Details
Main Authors:	Ashok Vaid, Raja T., Ullas Batra, Vamshi Muddu Krishna, Bharath Rangrajan, Prasad Narayanan, Amish Vora, Suresh H. Advani
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-04-01
Series:	South Asian Journal of Cancer
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1756179

Similar Items

The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment
by: Mallikarjuna Siraganahalli Eshwaraiah, et al.
Published: (2023-06-01)

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
by: Kumar Prabhash, et al.
Published: (2023-12-01)

IEA EBC Annex83 Positive Energy Districts
by: Åsa Hedman, et al.
Published: (2021-03-01)

P014 Interim analysis of ELEANOR (n = 200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib
by: R. Bartsch, et al.
Published: (2023-03-01)

EBC-Estimator of Multidimensional Bayesian Threshold in Case of Two Classes
by: Oksana Kubaychuk
Published: (2020-09-01)

P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes
by: S. Johnston, et al.
Published: (2023-03-01)

GESTION DE LA INNOVACIÓN: UN RETO EN LA EBC
by: Juan C. Bermúdez Mora
Published: (2007-08-01)

23255 Devices Engineered to Collect Exhaled Breath Condensate (EBC) and their Applications
by: Alexander J. Schmidt, et al.
Published: (2021-03-01)

Clinical validation of an immunohistochemistry‐based CanAssist‐Breast test for distant recurrence prediction in hormone receptor‐positive breast cancer patients
by: Manjiri M. Bakre, et al.
Published: (2019-04-01)

Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method
by: Purvish Parikh, et al.
Published: (2023-07-01)

P126 Pathological complete response after neoadjuvant chemotherapy in patients with HER2 low and HER2 0 early breast cancer (eBC) – experience from Institute for Oncology and Radiology of Serbia (IORS)
by: O. Djurmez, et al.
Published: (2023-03-01)

Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
by: Xi Zhang, et al.
Published: (2023-04-01)

Hepatocellular carcinoma in India: Time for a new focus
by: Vamshi K Muddu, et al.
Published: (2023-01-01)

PENGEMBANGAN MUTU PENDIDIKAN MENGGUNAKAN PENDEKATAN PDCA TERHADAP SEKOLAH EBC FILIAL MAUBISSE
by: Alexandra de Araujo Tilman Tilman
Published: (2024-01-01)

Long-Term eBC Measurements with the Use of MAAP in the Polluted Urban Atmosphere (Poland)
by: Natalia Zioła, et al.
Published: (2021-06-01)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
by: Mark Pegram, et al.
Published: (2023-08-01)

Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer
by: ZHENG Fangchao, et al.
Published: (2022-07-01)

What HR decisions are crucial in turbulent times? An analysis of differences in manufacturing and non-manufacturing companies
by: Martin Šikyř, et al.
Published: (2023-06-01)

Detection of small delamination in mullite/Si/SiC model EBC system by pulse thermography
by: Yutaro Arai, et al.
Published: (2019-08-01)

Efficacy of chemotherapy in patients with HR+/HER2–Invasive lobular breast cancer
by: Marita Yaghi, et al.
Published: (2023-01-01)

Cifr/Ebced Metodunun Kur’ân Ayetlerine Tatbîki ve Ehl-i Beyt’le İlişkisi
by: Abdülkerim Seber
Published: (2004-12-01)

Debate: Percutaneous revascularization strategies for distal left main coronary artery disease. The EBC MAIN approach
by: Manuel Pan
Published: (2022-11-01)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
by: Daniel Stellato, et al.
Published: (2021-01-01)

Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients
by: Yuehua Liang, et al.
Published: (2024-01-01)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
by: Shohei Shikata, et al.
Published: (2023-11-01)

Wilderness Mass Casualty Incident (MCI): Rescue chain after avalanche at Everest Base Camp (EBC) in 2015
by: Zafren, K, et al.
Published: (2018)

Reference Ranges of 8-Isoprostane Concentrations in Exhaled Breath Condensate (EBC): A Systematic Review and Meta-Analysis
by: Yara Shoman, et al.
Published: (2020-05-01)

O Sistema de Rádios EBC no Cenário da Convergência Digital e da Conexão em Rede
by: Elton Bruno Barbosa Pinheiro
Published: (2018-06-01)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
by: Vanita Noronha, et al.
Published: (2016-08-01)

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
by: Lu-Qi Cao, et al.
Published: (2024-01-01)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
by: Nandini Dey, et al.
Published: (2021-01-01)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
by: Katarzyna J. Jerzak, et al.
Published: (2023-06-01)

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
by: Wei Wang MM, et al.
Published: (2023-05-01)

HR+/HER2– de novo metastatic breast cancer: a true peculiar entity?
by: Rosalba Torrisi, et al.
Published: (2023-03-01)

Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes
by: Marita Yaghi, MD, et al.
Published: (2022-08-01)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
by: Emma Zattarin, et al.
Published: (2023-04-01)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
by: Liliana Ascione, et al.
Published: (2022-10-01)

Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2− Early Breast Cancer
by: Hua Ni, et al.
Published: (2021-08-01)

An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report)
by: Martina Panebianco, et al.
Published: (2021-05-01)

Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
by: Katie Mycock, et al.
Published: (2021-01-01)